New Delhi, Feb. 6 -- Shares of Novo Nordisk rose more than 5% in pre-market trading on Friday, after Hims & Hers Health launched a compounded semaglutide pill, which came under scrutiny following an FDA warning against illegal copycat weight-loss drugs.

Just a day earlier, Hims & Hers Health announced that it will begin offering a lower-priced version of the new weight-loss pill. The news led to Novo's shares dipping as much as 7.5% on Thursday's trading session.

According to a report by Reuters, the telehealth firm said it will sell a copycat version of the drug starting at $49 a month through a subscription programme, whereas Novo sells the branded version, named Wegovy, for $149 a month.

Following the announcement, FDA Commissioner ...